Sustained discontinuation of infliximab with a raising-dose strategy after obtaining remission in patients with rheumatoid arthritis: the RRRR study, a randomised controlled trial

Tanaka Yoshiya; Oba Koji; Koike Takao; Miyasaka Nobuyuki; Mimori Tsuneyo; Takeuchi Tsutomu; Hirata Shintaro; Tanaka Eiichi; Yasuoka Hidekata; Kaneko Yuko; Murakami Kosaku; Koga Tomohiro; Nakano Kazuhisa; Amano Koichi; Ushio Kazuyasu; Atsumi Tatsuya; Inoo Masayuki; Hatta Kazuhiro; Mizuki Shinichi; Nagaoka Shouhei; Tsunoda Shinichiro; Dobashi Hiroaki; Horie Nao; Sato Norihiro

首页> 外文期刊>Annals of the Rheumatic Diseases: A Journal of Clinical Rheumatology and Connective Tissue Research >Sustained discontinuation of infliximab with a raising-dose strategy after obtaining remission in patients with rheumatoid arthritis: the RRRR study, a randomised controlled trial

【24h】

Sustained discontinuation of infliximab with a raising-dose strategy after obtaining remission in patients with rheumatoid arthritis: the RRRR study, a randomised controlled trial

机译：在获取类风湿性关节炎患者的缓解后，持续停止英夫利昔单抗与升降剂量策略：RRRR研究，随机对照试验

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Objectives The aim of this study is to determine whether the 'programmed' infliximab (IFX) treatment strategy (for which the dose of IFX was adjusted based on the baseline serum tumour necrosis factor alpha (TNF-alpha)) is beneficial to induction of clinical remission after 54 weeks and sustained discontinuation of IFX for 1 year.

机译：本研究的目的是确定“编程的”英夫利昔单抗（IFX）治疗策略（根据基线血清肿瘤坏死因子α（TNF-α）调整的IFX的剂量）是否有益于临床 54周后缓解，并持续停止IFX 1年。

著录项

来源
《Annals of the Rheumatic Diseases: A Journal of Clinical Rheumatology and Connective Tissue Research》 |2020年第1期|共9页
作者
Tanaka Yoshiya; Oba Koji; Koike Takao; Miyasaka Nobuyuki; Mimori Tsuneyo; Takeuchi Tsutomu; Hirata Shintaro; Tanaka Eiichi; Yasuoka Hidekata; Kaneko Yuko; Murakami Kosaku; Koga Tomohiro; Nakano Kazuhisa; Amano Koichi; Ushio Kazuyasu; Atsumi Tatsuya; Inoo Masayuki; Hatta Kazuhiro; Mizuki Shinichi; Nagaoka Shouhei; Tsunoda Shinichiro; Dobashi Hiroaki; Horie Nao; Sato Norihiro;
展开▼
作者单位

Univ Occupat &

Environm Hlth Dept Internal Med 1 Kitakyushu Fukuoka Japan;

Hokkaido Univ Hosp Clin Res &

Med Innovat Ctr Sapporo Hokkaido Japan;

Hokkaido Univ Grad Sch Med Dept Clin Immunol Sapporo Hokkaido Japan;

Tokyo Med &

Dent Univ Dept Rheumatol Tokyo Japan;

Ijinkai Takeda Gen Hosp Dept Rheumatol Kyoto Japan;

Keio Univ Sch Med Dept Rheumatol Tokyo Japan;

Hiroshima Univ Hosp Dept Clin Immunol &

Rheumatol Hiroshima Japan;

Tokyo Womens Med Univ Sch Med Dept Rheumatol Tokyo Japan;

Keio Univ Sch Med Dept Rheumatol Tokyo Japan;

Keio Univ Sch Med Dept Rheumatol Tokyo Japan;

Kyoto Univ Deapartment Rheumatol &

Clin Immunol Kyoto Japan;

Nagasaki Univ Dept Immunol &

Rheumatol Nagasaki Japan;

Univ Occupat &

Environm Hlth Dept Internal Med 1 Kitakyushu Fukuoka Japan;

Saitama Med Univ Saitama Med Ctr Dept Rheumatol Kawagoe Saitama Japan;

Ushio Clin Osaka Japan;

Hokkaido Univ Grad Sch Med Dept Clin Immunol Sapporo Hokkaido Japan;

Utazu Hama Clin Utazu Japan;

Tenri Hosp Dept Gen Med Tenri Nara Japan;

Matsuyama Red Cross Hosp Ctr Rheumat Dis Matsuyama Ehime Japan;

Yokohama Minami Kyosai Hosp Dept Rheumatol Yokohama Kanagawa Japan;

Hyogo Coll Med Div Rheumatol Nishinomiya Hyogo Japan;

Kagawa Univ Fac Med Div Hematol Rheumatol &

Resp Med Miki Kagawa Japan;

Hokkaido Univ Hosp Clin Res &

Med Innovat Ctr Sapporo Hokkaido Japan;

Hokkaido Univ Hosp Clin Res &

Med Innovat Ctr Sapporo Hokkaido Japan;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类免疫性疾病;
关键词

相似文献

外文文献
中文文献
专利

1. Sustained discontinuation of infliximab with a raising-dose strategy after obtaining remission in patients with rheumatoid arthritis: the RRRR study, a randomised controlled trial [J] . Tanaka Yoshiya, Oba Koji, Koike Takao, Annals of the Rheumatic Diseases: A Journal of Clinical Rheumatology and Connective Tissue Research . 2020,第1期

机译：在获取类风湿性关节炎患者的缓解后，持续停止英夫利昔单抗与升降剂量策略：RRRR研究，随机对照试验
2. Discontinuation of infliximab therapy in patients with Crohn's disease in sustained complete remission (the STOP IT study): protocol for a double-blind, randomised, placebo-controlled, multicentre trial [J] . Casper Steenholdt, J?rn Brynskov, Klaus Bendtzen, BMJ Open . 2014,第12期

机译：在持续完全缓解的克罗恩病患者中终止英夫利昔单抗治疗（STOP IT研究）：一项双盲，随机，安慰剂对照，多中心试验的方案
3. Discontinuation of infliximab therapy in patients with Crohn's disease in sustained complete remission (the STOP IT study): protocol for a double-blind, randomised, placebo-controlled, multicentre trial [J] . Casper Steenholdt, J?rn Brynskov, Klaus Bendtzen, BMJ Open . 2014,第12期

机译：在持续完全缓解的克罗恩病患者中终止英夫利昔单抗治疗（STOP IT研究）：一项双盲，随机，安慰剂对照，多中心试验的方案
4. Early disease control by low-dose prednisone comedication may affect the quality of remission In patients with early rheumatoid arthritis [C] . Monica Todoerti, Carlo Alberto Scire, Nicola Boffini, International Conference on the Neuroendocrine Immune Basis of the Rheumatic Diseases . 2010

机译：低剂量泼尼松的早期疾病控制可能会影响早期类风湿性关节炎患者的缓解质量
5. The Efficacy of Therapeutic Drug Monitoring of Rheumatoid Arthritis Patients on Infliximab [D] . Abolhosn, Rania. 2018

机译：类风湿性关节炎患者治疗药物监测对英夫利昔单抗的疗效
6. Remission induction by Raising the dose of Remicade in RA (RRRR) study: Rationale and study protocol for a randomized controlled trial comparing for sustained clinical remission after discontinuation of infliximab in patients with rheumatoid arthritis [O] . Koji Oba, Nao Horie, Norihiro Sato, 2017

机译：通过增加RA中的Remicade剂量来诱导缓解（RRRR）：风湿性关节炎患者中英夫利昔单抗停药后持续临床缓解比较的随机对照试验的理论和研究方案
7. Response to: ‘Comment on ‘Sustained discontinuation of infliximab with a raising-dose strategy after obtaining remission in patients with rheumatoid arthritis: the RRRR study, a randomised controlled trial’ by Tanaka et al’ by Berkhout et al [O] . Yoshiya Tanaka, Koji Oba, Tsutomu Takeuchi 2019

机译：回应：“评论对流血关节炎患者缓解后的提高剂量策略持续停止inciximab的持续停止：RRRR研究，Berkhout等人的随机对照试验”Tanaka等人“

Sustained discontinuation of infliximab with a raising-dose strategy after obtaining remission in patients with rheumatoid arthritis: the RRRR study, a randomised controlled trial

摘要

著录项

相似文献

相关主题

期刊订阅